Biotech Values

[jondoeuk]

Gritstone will be using a heterologous prime-boost regime. They will prime with a chimpanzee adenoviral vector and then boost using synthetic self replicating RNA. This has been shown to induce greater numbers of antigen specific T-cells and increases the quality of response by involving multiple subsets and cytokine profiles. With anti-CTLA4 in preclinical studies they have shown extremely high and sustained T-cell responses. This compares to T-cell numbers observed in successful ACT http://cancerres.aacrjournals.org/content/78/13_Supplement/724

Their in silico approach seems to produce better results than I expected http://cancerres.aacrjournals.org/content/78/13_Supplement/5722